Statistics

Total Visits

Views
Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER272

Select a period of time:

Number of views in the range

Views
Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER217

Views

Views
December 20251
January 20262
February 20261
March 20261
April 20260
May 20265
June 20267
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States10
Netherlands3
Ecuador1
Mexico1
Nigeria1
Venezuela1
 

Top cities views

Views
Groningen3
Las Vegas2
Abuja1
Fayetteville1
Miami1
Riobamba1
Tultitlán de Mariano Escobedo1